Valneva’s strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Valneva aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.
An integrated business model that has allowed to build a portfolio of differentiated assets as well as a robust commercial portfolio
- The Company is focused on utilizing its proven and validated product development capabilities to rapidly advance its late-stage clinical programs to regulatory approval and commercialization.
Investing in innovative R&D programs to meet unmet medical needs
- The Company is advancing its late stage portfolio, and also remains focused on investing in its research and development pipeline in order to develop its earlier stage assets as well as identify new targets and indications where Valneva believes it can make a significant difference.
Collaboration is often key to success in research and biotechnology
- Valneva has strategically entered into partnerships with other well-established pharmaceutical companies to leverage clinical and commercial capabilities to optimize the potential value of select assets.